Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations. Issue 5 (3rd February 2022)

• Record Type: Journal Article
• Authors: Ziemssen, Tjalf; Akgun, Katja; Członkowska, Anna; Antos, Agnieszka; Bembenek, Jan; Kurkowska‐Jastrzębska, Iwona; Przybyłkowski, Adam; Skowrońska, Marta; Smolinski, Lukasz; Litwin, Tomasz
• Is Part Of: Movement disorders. Volume 37:Issue 5(2022)
• Page Start: 1074
• Page End: 1079
• Publication Date: 2022-02-03
• Subjects: Wilson disease -- copper -- biomarkers -- magnetic resonance imaging -- neurofilament light chain; Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.28946
• Languages: English
• ISSNs: 0885-3185

Abstract

Abstract: Background: Clinical scales and neuroimaging are used to monitor nervous system injury in Wilson's disease, while data on serum markers are scarce. Objective: To investigate whether serum concentrations of neurofilament light chain (sNfL) correlate with brain injury in Wilson's disease patients. Methods: In 61 treatment‐naïve patients, the Unified Wilson's Disease Rating Scale and a validated semiquantitative brain magnetic resonance imaging scale were compared with concentrations of sNfL. Results: Concentrations of sNfL were significantly higher in patients with neurological disease compared with patients presenting with other forms (39.7 ± 73.4 pg/mL vs. 13.3 ± 9.2 pg/mL; P < 0.01). Moreover, the sNfL concentration positively correlated with neurological severity scores and with acute and chronic brain damage based on the neuroimaging scale. Conclusions: Neurofilament light chain concentrations may be used as a marker of brain injury in Wilson's disease, in addition to the clinical and neuroimaging disease severity scales. © 2022 International Parkinson and Movement Disorder Society